Cargando…

Inactivating SARS-CoV-2 Surrogates on Surfaces Using Engineered Water Nanostructures Incorporated with Nature Derived Antimicrobials

The continuing cases of COVID-19 due to emerging strains of the SARS-CoV-2 virus underscore the urgent need to develop effective antiviral technologies. A crucial aspect of reducing transmission of the virus is through environmental disinfection. To this end, a nanotechnology-based antimicrobial pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaze, Nachiket, Soorneedi, Anand R., Moore, Matthew D., Demokritou, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146109/
https://www.ncbi.nlm.nih.gov/pubmed/35630957
http://dx.doi.org/10.3390/nano12101735
_version_ 1784716479684411392
author Vaze, Nachiket
Soorneedi, Anand R.
Moore, Matthew D.
Demokritou, Philip
author_facet Vaze, Nachiket
Soorneedi, Anand R.
Moore, Matthew D.
Demokritou, Philip
author_sort Vaze, Nachiket
collection PubMed
description The continuing cases of COVID-19 due to emerging strains of the SARS-CoV-2 virus underscore the urgent need to develop effective antiviral technologies. A crucial aspect of reducing transmission of the virus is through environmental disinfection. To this end, a nanotechnology-based antimicrobial platform utilizing engineered water nanostructures (EWNS) was utilized to challenge the human coronavirus 229E (HCoV-229E), a surrogate of SARS-CoV-2, on surfaces. The EWNS were synthesized using electrospray and ionization of aqueous solutions of antimicrobials, had a size in the nanoscale, and contained both antimicrobial agents and reactive oxygen species (ROS). Various EWNS were synthesized using single active ingredients (AI) as well as their combinations. The results of EWNS treatment indicate that EWNS produced with a cocktail of hydrogen peroxide, citric acid, lysozyme, nisin, and triethylene glycol was able to inactivate 3.8 logs of HCoV-229E, in 30 s of treatment. The delivered dose of antimicrobials to the surface was measured to be in pico to nanograms. These results indicate the efficacy of EWNS technology as a nano-carrier for delivering a minuscule dose while inactivating HCoV-229E, making this an attractive technology against SARS-CoV-2.
format Online
Article
Text
id pubmed-9146109
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91461092022-05-29 Inactivating SARS-CoV-2 Surrogates on Surfaces Using Engineered Water Nanostructures Incorporated with Nature Derived Antimicrobials Vaze, Nachiket Soorneedi, Anand R. Moore, Matthew D. Demokritou, Philip Nanomaterials (Basel) Article The continuing cases of COVID-19 due to emerging strains of the SARS-CoV-2 virus underscore the urgent need to develop effective antiviral technologies. A crucial aspect of reducing transmission of the virus is through environmental disinfection. To this end, a nanotechnology-based antimicrobial platform utilizing engineered water nanostructures (EWNS) was utilized to challenge the human coronavirus 229E (HCoV-229E), a surrogate of SARS-CoV-2, on surfaces. The EWNS were synthesized using electrospray and ionization of aqueous solutions of antimicrobials, had a size in the nanoscale, and contained both antimicrobial agents and reactive oxygen species (ROS). Various EWNS were synthesized using single active ingredients (AI) as well as their combinations. The results of EWNS treatment indicate that EWNS produced with a cocktail of hydrogen peroxide, citric acid, lysozyme, nisin, and triethylene glycol was able to inactivate 3.8 logs of HCoV-229E, in 30 s of treatment. The delivered dose of antimicrobials to the surface was measured to be in pico to nanograms. These results indicate the efficacy of EWNS technology as a nano-carrier for delivering a minuscule dose while inactivating HCoV-229E, making this an attractive technology against SARS-CoV-2. MDPI 2022-05-19 /pmc/articles/PMC9146109/ /pubmed/35630957 http://dx.doi.org/10.3390/nano12101735 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vaze, Nachiket
Soorneedi, Anand R.
Moore, Matthew D.
Demokritou, Philip
Inactivating SARS-CoV-2 Surrogates on Surfaces Using Engineered Water Nanostructures Incorporated with Nature Derived Antimicrobials
title Inactivating SARS-CoV-2 Surrogates on Surfaces Using Engineered Water Nanostructures Incorporated with Nature Derived Antimicrobials
title_full Inactivating SARS-CoV-2 Surrogates on Surfaces Using Engineered Water Nanostructures Incorporated with Nature Derived Antimicrobials
title_fullStr Inactivating SARS-CoV-2 Surrogates on Surfaces Using Engineered Water Nanostructures Incorporated with Nature Derived Antimicrobials
title_full_unstemmed Inactivating SARS-CoV-2 Surrogates on Surfaces Using Engineered Water Nanostructures Incorporated with Nature Derived Antimicrobials
title_short Inactivating SARS-CoV-2 Surrogates on Surfaces Using Engineered Water Nanostructures Incorporated with Nature Derived Antimicrobials
title_sort inactivating sars-cov-2 surrogates on surfaces using engineered water nanostructures incorporated with nature derived antimicrobials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146109/
https://www.ncbi.nlm.nih.gov/pubmed/35630957
http://dx.doi.org/10.3390/nano12101735
work_keys_str_mv AT vazenachiket inactivatingsarscov2surrogatesonsurfacesusingengineeredwaternanostructuresincorporatedwithnaturederivedantimicrobials
AT soorneedianandr inactivatingsarscov2surrogatesonsurfacesusingengineeredwaternanostructuresincorporatedwithnaturederivedantimicrobials
AT moorematthewd inactivatingsarscov2surrogatesonsurfacesusingengineeredwaternanostructuresincorporatedwithnaturederivedantimicrobials
AT demokritouphilip inactivatingsarscov2surrogatesonsurfacesusingengineeredwaternanostructuresincorporatedwithnaturederivedantimicrobials